All In Biotech

Drug Trial Radar · NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)

Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

606

Planned (sponsor's estimate)

Start

Feb 28, 2022

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

Conditions

  • Leukemia, Myeloid, Acute
  • Leukemia, Lymphocytic, Acute
  • Multiple Myeloma
  • Myelodysplastic Syndromes

Interventions

  • EnzomenibDrug

    DSP-5336 orally

  • azolesDrug

    Posaconazole, Voriconazole, or Fluconazole

  • VenetoclaxDrug

    Venetoclax orally

  • GilteritinibDrug

    Gilteritinib orally

  • Azacitidine (AZA)Drug

    Azacitidine orally

  • Intensive chemotherapy with 7 + 3Drug

    chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events and serious adverse events in Phase 1Time frame: 30 days from last dose
  2. Determination of Recommended Phase 2 Dose (RP2D)Time frame: Within 4 months from first dose
  3. Determination of Recommended Phase 2 Dose (RP2D) for patients with relapse and refractory AML who are enrolled into the combination venetoclax and azacitidine armTime frame: Within 4 months from first dose
  4. Determination of Recommended Phase 2 Dose (RP2D) for patients with relapse and refractory AML who are enrolled into the gilteritinib armTime frame: Within 4 months from first dose
  5. Optimal dose of DSP-5336 (RP2D) for patients newly diagnosed with AML enrolled into the combination venetoclax and azacitidine armTime frame: Within 4 months from the first dose
  6. Determination of Recommended Phase 2 Dose (RP2D) for patients enrolled into the 7 + 3 armTime frame: Within 4 months from first dose
  7. Number of patients achieving complete response (CR) and complete response with partial hematologic recovery (CRh) in Phase 2Time frame: Approximately 6 months after first dose

Locations

104 sites in 12 countries. Site status is shown where the registry gives one.

  • Hoag Family Cancer Center

    Newport Beach, California · Recruiting

  • Stanford University

    Palo Alto, California · Not yet recruiting

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Not yet recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Not yet recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Not yet recruiting

  • Northwestern

    Chicago, Illinois · Recruiting

  • Sibley Memorial Hospital

    Baltimore, Maryland · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Main Center

    Baltimore, Maryland · Recruiting

  • Tufts University

    Boston, Massachusetts · Withdrawn

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Atlantic Health

    Morristown, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Mount Sinai Hospital

    New York, New York · Completed

  • Columbia University

    New York, New York · Completed

  • UNC Hospital

    Chapel Hill, North Carolina · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Atrium Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • TriStar Centennial Medical Center

    Nashville, Tennessee · Recruiting

  • MDACC

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Intermountain Healthcare

    Salt Lake City, Utah · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • ZNA Cadix

    Antwerp, Belgium · Recruiting

  • UZ Ghent

    Ghent, Belgium · Recruiting

  • University Hospitals Leuven

    Leuven, Belgium · Recruiting

  • AZ Delta

    Roeselare, Belgium · Recruiting

  • University of Alberta

    Edmonton, Canada · Recruiting

  • Tom Baker Cancer Center

    Calgary, Alberta, Canada · Recruiting

  • Centre Hospitalier Universitaire d'Angers

    Angers, France · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.